SecBot SecBot
8-K ·Filed Nov 5, 2026

HALO

HALOZYME THERAPEUTICS, INC.
BULLISH
Impact 6/10
Horizonweeks Processed11d 11h ago SEC0001159036-26-000143
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong royalty growth signal continued momentum from ENHANZE partnered products. The Dutch patent win against Merck protects a key revenue stream. Watch for further patent developments and partner pipeline progress (12 ENHANZE programs in development).

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

HALO drug pipeline →

DARZALEX Faspro

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available since 2020, with multiple FDA-approved indications. No additional regulatory milestones are pending for this specific product.
Next catalyst
None dated

What to watchDARZALEX Faspro is an already-approved, commercially mature product with no upcoming binary catalyst for Halozyme. The next stock-moving events for Halozyme are quarterly royalty reports and the Merck Keytruda Qlex patent litigation outcome. Investors should watch J&J's quarterly daratumumab sales figures and Halozyme's Q4 2026 earnings for royalty growth trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$103.63
T+0 close · Nov 5, 2026 · via day close
Latest settled
−3.24%
T+5 · $100.27 · next T+20 in 20d
Vs SPY
−5.84%
α at T+5
Latest observation
−6.55%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $103.63entry
  2. T+1 · 8d ago −0.69%α −3.05% · $102.92
  3. T+5 · 4d ago −3.24%α −5.84% · $100.27
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Halozyme reported Q3 2026 total revenue of $493M (+39% YoY) and non-GAAP EPS of $2.39, beating consensus estimates of $2.36. The company raised its full-year 2026 guidance across all metrics, reflecting strong royalty revenue growth of 44% YoY. A Dutch patent court injunction against Merck's Keytruda Qlex launch in multiple European markets was also announced.

Key Financial Metrics

EPS (Adj.)
$2.39
est $2.36 · +1.3% · GAAP: $2.01
Revenue
$493.0M
est $491.6M · +0.3% · +39.2% YoY
Rating
in line
Guidance
$1.860B-$1.925B
raised
Gross Margin
83.3%

Key Facts

  • Total revenue $493.0M, up 39% YoY from $354.3M
  • Royalty revenue $341.0M, up 44% YoY from $236.0M
  • Non-GAAP diluted EPS $2.39 vs consensus $2.36 (beat)
  • GAAP diluted EPS $2.01 vs $1.43 YoY
  • Full-year 2026 guidance raised: total revenue $1.860B-$1.925B, non-GAAP EPS $8.75-$9.05
  • Dutch patent court found Merck infringing MDASE patent, granted injunction on Keytruda Qlex in 8 European markets
  • Completed $400M in share repurchases in 2026
  • Cash and securities $1.08B at quarter end

Financial Impact

Revenue beat consensus by ~$1.4M; guidance raised by $25M-$15M at midpoint for revenue and $0.10-$0.05 for non-GAAP EPS

revenueepsguidance

Risk Factors

  • Patent litigation outcomes remain uncertain outside the Dutch ruling
  • Reliance on partner product sales for royalty revenue
  • Convertible notes increase debt; stockholders' deficit of $55.2M

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001159036-26-000143
Document: halo-20261105.htm0001159036-26-000143
Document: 0001159036-26-000143-index-headers.html0001159036-26-000143
Document: 0001159036-26-000143-index.html0001159036-26-000143
Document: 0001159036-26-000143.txt0001159036-26-000143
8-K Data (Synthetic)0001159036-26-000143

Track record

15 reports on HALO

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
  2. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  4. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
  5. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
  6. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  7. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  8. Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  9. Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  10. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026